Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Dechra Pharmaceuticals Plc LSE:DPH London Ordinary Share GB0009633180 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  50.00 1.63% 3,114.00 383,792 16:35:04
Bid Price Offer Price High Price Low Price Open Price
3,092.00 3,096.00 3,102.00 3,018.00 3,054.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 608.00 74.00 51.33 60.7 3,543
Last Trade Time Trade Type Trade Size Trade Price Currency
18:17:02 O 592 3,114.311 GBX

Dechra Pharmaceuticals (DPH) Latest News

More Dechra Pharmaceuticals News
Dechra Pharmaceuticals Investors    Dechra Pharmaceuticals Takeover Rumours
Smart Money!
DPH is a large holding in the following funds:
 Fund  Percentage of Fund  Last Updated 
 BLACKROCK THROGMORTON TRUST PLC 2.40% 2022-03-31

Dechra Pharmaceuticals (DPH) Discussions and Chat

Dechra Pharmaceuticals Forums and Chat

Date Time Title Posts
02/2/202308:23Dechra Pharmaceuticals Plc580
10/3/201216:11LOOKING TO BUY DECHRA PHARMACEUTICAL88
10/3/201216:10Dechra with Charts9
10/3/201216:10Dechra Pharmaceuticals PLC1

Add a New Thread

Dechra Pharmaceuticals (DPH) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Dechra Pharmaceuticals trades in real-time

Dechra Pharmaceuticals (DPH) Top Chat Posts

Top Posts
Posted at 04/2/2023 08:20 by Dechra Pharmaceuticals Daily Update
Dechra Pharmaceuticals Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DPH. The last closing price for Dechra Pharmaceuticals was 3,064p.
Dechra Pharmaceuticals Plc has a 4 week average price of 2,504p and a 12 week average price of 2,504p.
The 1 year high share price is 4,310p while the 1 year low share price is currently 2,488p.
There are currently 113,763,838 shares in issue and the average daily traded volume is 412,875 shares. The market capitalisation of Dechra Pharmaceuticals Plc is £3,542,605,915.32.
Posted at 05/9/2022 14:04 by km18
Dechra Pharmaceuticals Plc posted Prelims for the FY ended 30th June 2022. Revenues grew 13.8% to £681.8 million, reported operating profit rose 16.2% to £95.5m, underlying diluted EPS increased 14.0% to 120.84 pence and the FY dividend increased by 10.8% to 44.89 pence, all at constant exchange rate. The business has been growing solidly for many years now, but valuation remains unhelpful with forward PE ratio at 27.9x and PS ratio at 6.21x. Share price has been in a correction for most of 2022 and this correction has extended another 10%+ following today’s release. DPH is a high quality and solid growth business, but it is expensive and a share to monitor for now...

...from WealthOracle

https://wealthoracle.co.uk/detailed-result-full/DPH/541

Posted at 02/8/2022 08:08 by spyder
Anyone know what has rattled DPH this morning?
Posted at 22/7/2022 07:11 by steeplejack
I can understand why in these markets,but a discount of 8% for a placing of less than 5% new equity is large.A placing discount of 3% would have been sufficient.Added to holding at generous price.
Posted at 21/7/2022 08:18 by prokartace
I have used this opportunity to buy into the share via primary bid. Was a little shocked to get 100% allotment but happy enough.
Posted at 04/5/2022 17:44 by roguetraderuk
st, the ones you mention are all high multiple names esp for the uk mkt. when price of money is repriced so are these. on top of that youve got extra risk repricing from the back end of covid and the war which is leading to a global economic slowdown. ive never been able to buy halma over the years, i always ended up picking up something similarly positioned re growth. most recently during the covid drop i weighed up halma and ashtead, plumping for the latter eventually. now out of that and looking for a re entry at some point this year. but the point is the high multiple names dont tend to work when yields are going up. eventually they will stop and thats the time to step in imo.
Posted at 04/5/2022 17:16 by steeplejack
I suppose Dechra is something of a covid play in that pet ownership increased significantly during the epidemic.Will owners abandon their furry four legged friends now the epidemic is tailing off?Unlikely i would have thought.This company is an obvious beneficiary of sterling weakness of course.Sterling has weakened over ten cents or some 9% since the interim stage but the market is ignoring that.Sadly,Dechra is vulnerable to general disillusionment with equities along with the likes of Croda,Halma etc which similarly still well up on where they were trading a couple of years ago.There's a strong case for simply shoving off for the Summer and ignoring equity markets.There are too many negative headwinds,algorithmic trading dominating day to day trading.It's impossible to rationalise some of the price moves dictated as they are by a simple deleveraging of markets.
Posted at 14/4/2022 15:37 by steeplejack
Ah there’s a sale of 92/- odd….that might explain it.Pretty lousy price achieved.

So on reflection,it looks like some fund manager found himself compelled to sell stock on the last trading day before Easter as a result perhaps of redemption requirements,a sudden bout of nerves,a damascene experience or simple stupidity.For whatever reason selling some 4 million quids worth of Dechra on the afternoon before a bank holiday in a quiet market smacks of irresponsibilityR30;.. but who knows what the future holds.

Posted at 21/2/2022 13:18 by km18
Dechra Pharmaceuticals issued its HY Financial Report this morning. Reported Group revenue for the period increased by 15.9% to £332.4m at Constant Exchange Rate (CER). Underlying operating profit growth was 22.0% with underlying operating margin improving by 140 bps to 28.2%. Underlying diluted EPS growth was 24.0% to 64.01p and the interim dividend increased by 8.0% to 12 pence. So more robust growth and more profitable growth.

The business has been growing briskly and profitably for many years now and looks set to continue this pattern in FY22 as well. Unsurprisingly investors have already bought into the story, valuation is rich with forward PE ratio around 31 and bottom quartile for the Pharma sector. The share price is also currently in a 30%+ correction and still falling after a powerful post-Covid rally. DPH is a very good company delivering persistent and robust growth, but there is no rush to buy. Monitor for the time being....

...from WealthOracleAM

https://wealthoracle.co.uk/detailed-result-full/DPH/361

Posted at 17/2/2022 07:46 by spyder
I have been following Dechra for years, but only just bought some shares.
FWIW, then look oversold to me, the pandemic increase in pet numbers (both in the UK and US) together with increased veterinary activity is not ‘over’, it will be sustained.
The only thing that IS over is the onetime jump in the growth rate, I expect now to see a resumption of more normal rates of growth, albeit from a higher base.
The share are effectively below pre-pandemic multiples and that makes no sense to me.

Posted at 13/1/2022 10:34 by lindowcross
I'm not a follower or believer in chart analysis but it's not hard to see from the graph that since 2018 there has been 6-7 "dips" in the share price. Despite this the overall trajectory remains upward. Best to buy on the dips with a successful company like this.
Dechra Pharmaceuticals share price data is direct from the London Stock Exchange
Your Recent History
LSE
DPH
Dechra Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230205 04:15:54